Results 51 to 60 of about 2,134,276 (240)

USP4‐Dependent CHAF1B Stabilization Regulates Distinct SETDB1 Ubiquitin States Linked to AKT T308 Signaling and Lipogenic Remodeling in HCC

Advanced Science, EarlyView.
USP4 stabilizes CHAF1B by limiting K48‐linked ubiquitination. Stabilized CHAF1B supports UHRF1‐associated K63‐linked SETDB1 ubiquitination and cytoplasmic redistribution, whereas CHAF1B loss favors VHL‐dependent K11‐associated degradative ubiquitination and proteasomal loss of SETDB1.
Saiyan Bian, Yun Tong, Wenkai Ni, Zhangzhi Tang, Weiting Chen, Kexin Ma, Lihan Jiang, Jiayu Shao, Xuyang He, Wenjie Zheng   +9 more
wiley   +1 more source

Increasing Familial Retinoblastoma in High-Income Countries despite Stable Overall Incidence, 2017 to 2024. [PDF]

To reassess retinoblastoma (RB) incidence in high-income countries (HICs) participating in the Global Retinoblastoma Study and evaluate temporal changes in the proportion of familial RB between 2017 and 2024. Multicenter repeated cross-sectional study.
Stathopoulos, Christina, Chawla, Bhavna, Al-Jadiry, Mazin Faisal, Dalvin, Lauren A, Bowman, Richard, Fabian, Ido Didi, Benvenuto, Franco, Cassoux, Nathalie, Sandri, Lara, Ademola-Popoola, Dupe S, Chaudhry, Shabana, Susanty, Anne, Essuman, Vera Adobea, Lustig-Barzelay, Yael, Staffieri, Sandra Elfride, Bansal, Rolika, Comsa, Codruta, Global Retinoblastoma Study Group   +17 more
core   +1 more source

Patient‐Derived Glioblastoma Organoids for AI‐Guided Prediction of Therapeutic Response

Advanced Science, EarlyView.
Patient‐derived glioblastoma organoids provide clinically relevant models that preserve tumor heterogeneity and enable integrated AI‐driven analysis of imaging, molecular, and treatment‐response data. Their convergence with advanced analytics supports predictive, personalized therapeutic strategies and may accelerate translation from patient‐specific ...
Sandbhor Puja, Arun Bhavyadharshini, John Geofrey, Mudliyar Siddharth, Ghanekar Shubham, Moyiadi Aliasgar, Shetty Prakash, Singh Vikas, Sadwani Nidhisha, Garg Akshohini, Sahay Ayushi, Chatterjee Abhishek, Epari Sridhar, Gupta Tejpal, Dasgupta Archya, Goda Jayant   +15 more
wiley   +1 more source

Inhibition of Mahkota Dewa (Phaleria macrocarpa) bioactive fraction on proliferation of human retinoblastoma tumor cells Y-79 through suppression of mRNA level of cyclin E

Asian Pacific Journal of Tropical Biomedicine, 2017
Objective: To prove the molecular mechanisms of Mahkota Dewa (Phaleria macrocarpa) in suppressing proliferation of human retinoblastoma cells through suppression of cell cycle's gene-regulators expression.
Nugroho Trilaksana, Ignatius Riwanto, Raymond Rubianto Tjandrawinata, Reki Winarto   +3 more
doaj   +1 more source

A UBE3A‐UTX Proteostasis‐Epigenetic Axis Governs Hypothalamic Energy Homeostasis

Advanced Science, EarlyView.
Ubiquitin protein ligase E3A (UBE3A) regulates hypothalamic energy homeostasis and promotes degradation of the histone demethylase UTX (KDM6A). Neuronal UBE3A loss increases susceptibility to diet‐induced obesity and is accompanied by UTX accumulation, reduced histone H3 lysine 27 trimethylation, and altered endoplasmic reticulum stress‐responsive gene
Junekyoung Lee, Jaeyoung Yoo, Young A. Kim, Zhuodu Wei, Yunseo Lee, Woo‐Jeong Shon, Je Kyung Seong, Seunghee Lee   +7 more
wiley   +1 more source

Insights into retinoblastoma pathogenesis: unraveling RB1, N-MYC and miRNA profiles

BMJ Open Ophthalmology
Objective Retinoblastoma is the most common paediatric intraocular malignancy, originating in neural retina germ cells. Early diagnosis is crucial for survival and eye preservation.
Mohammad Faranoush, Fatemeh Khesali, Pooya Faranoush, Mohammad Reza Foroughi-Gilvaee, Parisa Shams, Negin Sadighnia, Seyyed Amir Yasin Ahmadi, Dorsa Fallah Azad, Reza Nekouian   +8 more
doaj   +1 more source

Concurrent Germline RB1 & Mosaic TP53 in a Child With Multiple Childhood Cancers

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT We report a patient with a pathogenic germline variant (PGV) in RB1 and somatic mosaicism for a pathogenic TP53 variant who developed three distinct types of childhood cancer: retinoblastoma, osteosarcoma, and myelodysplastic syndrome (MDS) before the age of 6 years.
Ole Haubjerg Nielsen, Ulrik Kristoffer Stoltze, Pernille Axél Gregersen, Marianne Hoffmann, Morten Lyng Høgild, Mette Klarskov Andersen, Lise Barlebo Ahlborn, Lisa Lyngsie Hjalgrim, Karin A. W. Wadt   +8 more
wiley   +1 more source

A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma

Communications Biology
Retinoblastoma are childhood eye tumors arising from retinal precursor cells. Two distinct retinoblastoma subtypes with different clinical behavior have been described based on gene expression and methylation profiling.
Tatsiana Ryl, Elena Afanasyeva, Till Hartmann, Melanie Schwermer, Markus Schneider, Christopher Schröder, Maren Wagemanns, Arthur Bister, Deniz Kanber, Laura Steenpass, Kathrin Schramm, Barbara Jones, David T. W. Jones, Eva Biewald, Kathy Astrahantseff, Helmut Hanenberg, Sven Rahmann, Dietmar R. Lohmann, Alexander Schramm, Petra Ketteler   +19 more
doaj   +1 more source

Hematopoiesis specific loss of Cdk2 and Cdk4 results in increased erythrocyte size and delayed platelet recovery following stress

Haematologica, 2015
Mouse knockouts of Cdk2 and Cdk4 are individually viable whereas the double knockouts are embryonic lethal due to heart defects, and this precludes the investigation of their overlapping roles in definitive hematopoiesis.
Senthil Raja Jayapal, Chelsia Qiuxia Wang, Xavier Bisteau, Matias J. Caldez, Shuhui Lim, Vinay Tergaonkar, Motomi Osato, Philipp Kaldis   +7 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source